Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
MINNEAPOLIS - Bio-Techne (NASDAQ:TECH) Corporation (NASDAQ: TECH), a life sciences company with a market capitalization of $10.42 billion and strong financial health indicators according to InvestingPro, has introduced a Good Manufacturing Practice (GMP) grade transposase mRNA for its TcBuster genome engineering system, a move that could streamline the creation of cell-based therapies. This system is designed to facilitate gene editing in immune and stem cell therapies without the use of viral vectors.
The TcBuster system, which employs a non-viral approach to introduce genetic modifications, is noted for its capability to deliver multiple genes simultaneously with high efficiency. The newly released GMP transposase is anticipated to provide a more direct route to clinical application for treatments such as chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR) therapies.
Will Geist, President of Bio-Techne's Protein Science Segment, stated that the GMP TcBuster transposase is a significant advancement for cell therapy developers, offering an efficient gene editing tool that avoids the limitations of traditional viral delivery methods.
Bio-Techne emphasizes that the TcBuster system presents several advantages over traditional lentivirus-based methods, including a hyperactive enzyme through protein engineering, a reduced insertional risk profile, and the elimination of the need for viral clearance. This could lead to reduced time to market and lower costs for developers of cell therapies.
The GMP TcBuster transposase is now available for purchase, and Bio-Techne touts a robust supply chain for both research-use-only (RUO) and GMP grade reagents. The system is compatible with various cell types and has applications in autologous and allogeneic cell therapies, as well as in bioprocessing cell lines for therapeutic biologics production.
Bio-Techne, a global life sciences company, reported approximately $1.2 billion in net sales for fiscal 2024 and employs around 3,100 individuals worldwide. The company maintains healthy financials with a current ratio of 3.94 and revenue growth of 4.46% over the last twelve months. While trading at relatively high earnings multiples, InvestingPro analysis reveals 10 additional key investment insights available to subscribers. The company's portfolio includes a wide range of products that support scientific research and clinical diagnostics.
This development is based on a press release statement from Bio-Techne Corporation. For a comprehensive analysis of Bio-Techne's financial health, valuation metrics, and growth prospects, investors can access the detailed Pro Research Report available exclusively on InvestingPro, which provides expert insights on this and over 1,400 US-listed companies.
In other recent news, Bio-Techne Corp has reported a strong Q4 2024, surpassing analysts' earnings per share (EPS) estimates. The company posted an EPS of $0.42, beating the forecast of $0.39. Additionally, Bio-Techne's revenue reached $297 million, exceeding the expected $286.14 million. The positive results reflect the company's robust financial performance and solid business operations.
Bio-Techne demonstrated a significant increase in EBITDA, rising to $21.3 million, up $11 million from the previous year. This growth was supported by strategic initiatives, including the launch of DeviceNow and the formation of various partnerships. The company also reported a positive cash flow from operations, enhancing its financial stability.
Despite potential concerns over guidance revisions, Bio-Techne remains committed to its growth trajectory and strategic goals. The company anticipates double-digit growth in recurring revenue and net gross profit for 2025, with acceleration expected through 2026. CEO Morten Maier reassured investors, stating there are no plans to adjust the guidance for 2025 negatively. These are the latest developments in Bio-Techne's recent performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.